Innovative

Three essentials for achieving 5-year results

Only Zilver PTX combines an antiproliferative drug with, polymer-free drug delivery and vessel support to demonstrate superior 5-year results against PTA and Zilver bare-metal stents.¹

When drug elution is most needed

Short-term paclitaxel delivery in the SFA has been proven beneficial.

How drug elution works

Zilver PTX is the only polymer-free SFA drug-eluting stent. Our proprietary, polymer-free coating process is shown to be safe and effective while eliminating the potential risks associated with permanent polymers.

Release

More than 98% of the paclitaxel coating is released from the stent within 72 hours.^*3

6128278489001

brightcove

true

Absorption

Paclitaxel remains in the artery through 56 days.^*

Inhibiting

Inside the cell, the drug binds to microtubules and inhibits mitosis.^*

*Based on pharmokinetic studies in porcine models

Broad offering

Treat a wider range of patients and lesions 

Zilver PTX will enable you to standardize your drug-elution program and reduce the number of suppliers on the shelf. Zilver PTX offers more size configurations and indications for longer lesion lengths than Eluvia, enabling you to treat more patients with Zilver PTX.

·  Available in 5, 6, 7, and 8 mm diameters

·  Available in lengths up to 140 mm 

·  Approved for lesion lengths up to 300 mm

*Size availability as of June 2025

ELUVIA is a registered trademark of Boston Scientific Corporation or its affiliates. Learn more here.

1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472-1483.
2. Axel D, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96(2):636–645.
3. Dake MD, Van Alstine WG, Zhou Q, et al. Polymer-free paclitaxel-coated Zilver PTX stents—evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011;22(5):603-610.
4. Dake M, Ansel GM, Bosiers M, et al. Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all cause mortality compared to uncoated devices. Cardiovasc Intervent Radiol. 2019;43:8 –19.
5. Litsky J, Chanda A, Stilp E, et al. Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent. Med Devices (Auckl). 2014;7:149-156.
6. Nikol S, Huehns TY, Höfling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis. 1996;123(1-2):17-31.